Condition
Anemia in patients with very low, low or intermediate risk myelodysplastic neoplasms (MDS)
Total Trials
1
Recruiting
0
Active
1
Completed
0
Key Insights
Highlights
Treatment Research
1 treatments under study, led by Rvu120 Sel120
Research Leaders
8 sponsors active, led by University of Salamanca
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 1 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
1Total
Phase 2 (1)
Trial Status
Active Not Recruiting1
Clinical Trials (1)
Showing 1 of 1 trials
Showing all 1 trials
Research Network
Common Treatments
- Rvu120 Sel1201
Active Sponsors
- University of Salamanca1
- European Myelodysplastic Neoplasms Cooperative Group1
- GCP-Service International West GmbH1
- Ryvu Therapeutics SA1
- Medical University of Warsaw1
Top Investigators
Service d'hématologie seniors Hôpital Saint-Louis, Paris
Universitätsklinikum Leipzig
University of Careggi, Italy
Medical University of Warsaw
University of Salamanca
Related Conditions
- Low Risk Myelodysplastic Syndromes1